2-Amino-6-propyl-3H-pteridin-4-one | 36474-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 2-Amino-6-propyl-3H-pteridin-4-one
• 英文别名: 2-amino-6-propyl-3H-pteridin-4-one
• CAS: 36474-00-7
• 化学式: C₉H₁₁N₅O
• 分子量: 205.219
• InChiKey: XIAJHQBJXKQCPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Amino-6-propyl-3H-pteridin-4-one 在 platinum(IV) oxide 氢气 作用下， 以 盐酸 、 乙醇 为溶剂， 20.0 ℃ 、95.99 kPa 条件下， 生成 6-n-propyl-5,6,7,8-tetrahydropterin hydrochloride
  参考文献：
  名称：

  The dihydropteridine reductase (human brain) activity of some lipophilic quinonoid dihydropterins

  摘要：

  DOI：

  10.1016/0223-5234(87)90001-8

文献信息

• [EN] TOPOISOMERASE POISONS<br/>[FR] POISONS DE TOPOISOMÉRASE
  申请人：UNIV RUTGERS

  公开号：WO2017176648A1

  公开（公告）日：2017-10-12

  Provided herein are compounds of formula (I): and salts thereof. Also provided are pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I), and therapeutic methods for treating diseases such as cancer, a bacterial infection or a fungal infection using compounds of formula (I).

  本文提供的是式(I)的化合物及其盐。还提供了包括式(I)的化合物的药物组合物，制备式(I)的化合物的方法，制备式(I)的有用中间体，以及使用式(I)的化合物治疗疾病（如癌症、细菌感染或真菌感染）的治疗方法。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• SELECTIVE INHIBITION OF C4-PEP CARBOXYLASES
  申请人：Heinrich Heine Universitat Dusseldorf

  公开号：US20150216167A1

  公开（公告）日：2015-08-06

  The present invention relates to the use of a compound, a salt or solvate thereof as C4 plant selective herbicide wherein said compound comprises a cyclic alkyl, aryl, heterocycloalkyl or heteroaryl group, and wherein said compound further comprises a) at least a functional group Z being —C(═Y z )R 1 , wherein Y z is selected from the group consisting of O, NH and S, preferably wherein Y z is O, and wherein R 1 is selected from the group consisting of H, OH and N(R 2 R 3 ), —O(R 2 ) and —S(R 2 ), wherein R 2 and R 3 , are independently of each other, selected from the group consisting of H, alkyl, cycolalkyl, aryl and heteroaryl and a functional group Q which is —C(═Y Q )R 4 , wherein Y Q is selected from the group consisting of O, NH and S, preferably wherein Y Q is O, and wherein R 4 is selected from the group consisting of H, OH and NR 4# R 5# , OR 4# , SR 4# wherein R 4# and R 5# , are independently of each other, selected from the group consisting of H, alkyl, cycloalkyl, aryl and heteroaryl, or b) at least one electron donating group selected from the group consisting of OH, —SH, —O—R p , S—R p —NR p R q and O—C(═Y p )R r , wherein R p and R q are, independently of each other, selected from the group consisting of H, alkyl, cycloalkyl and heteroaryl, and wherein R r is —OH, —NH 2 , —NH-Alkyl, —O-Alkyl or —NH-Alkyl, and wherein Y p is selected from the group consisting of —S—, —O—, —NH, said compound being capable of binding to the malate binding site comprised by a phosphoenolpyruvate carboxylase from a C4 plant, thereby inhibiting said phosphoenolpyruvate carboxylase, and wherein the cyclic alkyl, aryl, heterocycloalkyl or heteroaryl group inhibits binding to the malate binding site of a phosphoenolpyruvate carboxylase from a C3 plant.
• CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
  申请人：The California Institute for Biomedical Research

  公开号：US20180104354A1

  公开（公告）日：2018-04-19

  Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.
• The dihydropteridine reductase (human brain) activity of some lipophilic quinonoid dihydropterins
  作者：Paul Waring、Wilfred L.F Armarego

  DOI：10.1016/0223-5234(87)90001-8

  日期：1987.3